Effect of c-met inhibitor SU11274 on hepatocellular carcinoma cell growth

BioScience Trends

Volumn 5, Issue 2, 2011, Pages 52-56

  Inagaki, Yoshinori ^a   Qi, Fanghua ^a   Gao, Jianjun ^a,b   Qu, Xianjun ^b   Hasegawa, Kiyoshi ^a   Sugawara, Yasuhiko ^a   Tang, Wei ^a,b   Kokudo, Norihiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b SHANDONG UNIVERSITY   (China)

Author keywords

c Met; Des carboxyprothrombin (DCP); Growth; Hepatocellular carcinoma (HCC); Inhibitor

Indexed keywords

((3Z) N (3 CHLOROPHENYL) 3 ((3,5 DIMETHYL 4 ((4 METHYLPIPERAZIN 1 YL)CARBONYL) 1H PYRROL 2 YL)METHYLENE) N METHYL 2 OXO 2,3 DIHYDRO 1H INDOLE 5 SULFONAMIDE); ((3Z)-N-(3-CHLOROPHENYL)-3-((3,5-DIMETHYL-4-((4-METHYLPIPERAZIN-1-YL)CARBONYL)-1H-PYRROL-2-YL)METHYLENE)-N-METHYL-2-OXO-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE); INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTHROMBIN; SCATTER FACTOR RECEPTOR; SULFONAMIDE;

ARTICLE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INDOLES; LIVER NEOPLASMS; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTHROMBIN; PROTO-ONCOGENE PROTEINS C-MET; SULFONAMIDES;

EID: 82255179972     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2011.v5.2.52     Document Type: Article

References (25)

1. Di Renzo MF, Narsimhan RP, Olivero M, Bretti S, Giordano S, Medico E, Gaglia P, Zara P, Comoglio PM. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene. 1991; 6:1997-2003.
2. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989; 342:440-443.
3. Gohda E, Tsubouchi H, Nakayama H, Hirono S, Sakiyama O, Takahashi K, Miyazaki H, Hashimoto S, Daikuhara Y. Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. J Clin Invest. 1988; 81:414-419.
4. Lee KH, Choi EY, Hyun MS, Eun JR, Jang BI, Kim TN, Lee HJ, Lee DS, Yun SS, Kim HJ, Kim JH, Kim JR. Cellular mechanisms of hepatocyte growth factormediated urokinase plasminogen activator secretion by MAPK signaling in hepatocellular carcinoma. Tumori. 2008; 94:523-530.
5. 2 hepatoma cell proliferation. J Biol Chem. 2008; 283:1428-1436.
6. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010; 29:4989-5005.
7. Suzuki K, Hayashi N, Yamada Y, Yoshihara H, Miyamoto Y, Ito Y, Ito T, Katayama K, Sasaki Y, Ito A, Kisida Y, Kashiwagi T, Fusamoto H, Kamada T. Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology. 1994; 20:1231-1236.
8. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology. 1997; 25:619-623.
9. D'Errico A, Fiorentino M, Ponzetto A, Daikuhara Y, Tsubouchi H, Brechot C, Scoazec JY, Grigioni WF. Liver hepatocyte growth factor does not always correlate with hepatocellular proliferation in human liver lesions: Its specific receptor c-met does. Hepatology. 1996; 24:60-64.
10. Zhang SZ, Pan FY, Xu JF, Yuan J, Guo SY, Dai G, Xue B, Shen WG, Wen CJ, Zhao DH, Li CJ. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther. 2005; 4:1577-1584.
11. Xie B, Xing R, Chen P, Gou Y, Li S, Xiao J, Dong J. Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference. J Surg Res. 2010; 162:231-238.
12. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-gamma-carboxy prothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology. 2003; 37:1114-1121.
13. Wang CS, Lin CL, Lee HC, Chen KY, Chiang MF, Chen HS, Lin TJ, Liao LY. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma. World J Gastroenterol. 2005; 11:6115-6119.
14. Ikoma J, Kaito M, Ishihara T, Nakagawa N, Kamei A, Fujita N, Iwasa M, Tamaki S, Watanabe S, Adachi Y. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum desgamma-carboxy prothrombin: A prospective study. Hepatogastroenterology. 2002; 49:235-238.
15. Kim do Y, Paik YH, Ahn SH, Youn YJ, Choi JW, Kim JK, Lee KS, Chon CY, Han KH. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology. 2007; 72:52-57.
16. Inagaki Y, Tang W, Xu H, Wang F, Nakata M, Sugawara Y, Kokudo N. Des-gamma-carboxy prothrombin: Clinical effectiveness and biochemical importance. Biosci 56 Trends. 2008; 2:53-60.
17. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Yamaguchi A, Isogai M, Kaneoka Y, Washizu J. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006; 4:111-117.
18. Yamamoto K, Imamura H, Matsuyama Y, Hasegawa K, Beck Y, Sugawara Y, Makuuchi M, Kokudo N. Significance of alpha-fetoprotein and Des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol. 2009; 16:2795-2804.
19. Gao FJ, Cui SX, Chen MH, Cheng YN, Sun LR, Ward SG, Kokudo N, Tang W, Qu XJ. Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cells. Life Sci. 2008; 83:815-820.
20. Suzuki M, Shiraha H, Fujikawa T, Takaoka N, Ueda N, Nakanishi Y, Koike K, Takaki A, Shiratori Y. Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem. 2005; 280:6409-6415.
21. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K, Christensen JG, Salgia R. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 2003; 63:5462-5469.
22. Qi FH, Li AY, Lv H, Zhao L, Li JJ, Gao B, Tang W. Apoptosis-inducing effect of cinobufacini, Bufo bufo gargarizans Cantor skin extract, on human hepatoma cell line BEL-7402. Drug Discov Ther. 2008; 2:339-343.
23. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005; 225:1-26.
24. Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, Hill J, Moussa MM, Leggett DS, Li CJ. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther. 2010; 9:1544-1553.
25. Nakagawa T, Tohyama O, Yamaguchi A, Matsushima T, Takahashi K, Funasaka S, Shirotori S, Asada M, Obaishi H. E7050: A dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci. 2010; 101:210-215.